

## DAFTAR PUSTAKA

- Agarwal, S., Sharma, M.C., Jha, P., Pathak, P., Suri, V., Sarkar, C., Chosdol, K., Suri, A., Kale, S.S., Mahapatra, A.K., Jha, P., 2013. Comparative study of IDH1 mutations in gliomas by immunohistochemistry and DNA sequencing. *Neuro-Oncology* 15, 718–726. doi:10.1093/neuonc/not015.
- Capper, D., Weibert, S., Balss, J., Habel, A., Meyer, J., Jager, D., Ackermann, U., Tessmer, C., Khorsunov, A., Zentgraf, A., Hartmann, A., Deimling, A.V., 2010. Characterization of R132H Mutation-specific IDH1 Antibody Binding in Brain Tumors. *Brain Pathology* 20, 245-254.
- Cohen, A.L., Holmen, S.L., Colman, H., 2013. IDH1 and IDH2 Mutations in Gliomas. *Current Neurology and Neuroscience Reports* 13. doi:10.1007/s11910-013-0345-4.
- Combs, S.E., Rieken, S., Wick, W., Abdollahi, A., von Deimling, A., Debus, J., Hartmann, C., 2011. Prognostic significance of IDH-1 and MGMT in patients with glioblastoma: one step forward, and one step back? *Radiation oncology* 6, 115.
- Dimitrov, L., Hong, C.S., Yang, C., Zhuang, Z., Heiss, J.D., 2015. New Developments in the Pathogenesis and Therapeutic Targeting of the IDH1 Mutation in Glioma. *International Journal of Medical Sciences* 12, 201–213. doi:10.7150/ijms.11047.
- Gown, A.M., 2016. Diagnostic Immunohistochemistry: What can go wrong and how to prevent it. *Arch Pathol Lab Med* 180; 893-898.
- Hanif, F., Muzaffar, K., Perveen, K., Mahli, S.M., Simjee, S.U., 2017. Glioblastoma Multiforme: A Review of its Epidemiology and Pathogenesis through Clinical Presentation and Treatment. *Asian Pacific Journal of Cancer Prevention*, 18(1): 3-9.
- Ichimura, K., Pearson, D.M., Kocialkowski, S., Backlund, L.M., Chan, R., Jones, D.T.W., Collins, V.P., 2009. IDH1 Mutation are present in Majority of Common Adult Gliomas but Rare in Primary Glioblastomas. *Neuro-Oncology*, 2009.
- Ikota, H., Nobusawa, S., Arai, H., Kato, Y., Ishizawa, K., Hirose, T., Yokoo, H., 2015. Evaluation of IDH1 status in diffusely infiltrating gliomas by immunohistochemistry using anti-mutant and wild type IDH1 antibodies. *Brain Tumor Pathology* 32, 237–244. doi:10.1007/s10014-015-0222-8.
- Frosch, M.P., Anthony, D.C., Girolami, U.D., 2012. *Pathologic Basis of Disease 9th Edition: The Central Nervous System* 28,1251-1318.
- Kato, Y., Jin, G., Kuan, C.T., Mc.Lendon, R.E., Yan, H., Bigner, D.D., 2009. A Monoclonal Antibody IMab-1 Specifically Recognizes IDH1 R132H, the Most Common Glioma-Derived Mutation. *Biochem Biophys Res Commun*, 390(3): 547-551.
- Kurian, K.M., Haynes, H.R., Crosby, C., Hopkins, K., Williams, M., 2013. IDH mutation analysis in glioma as a diagnostic and prognostic biomarker. *British Journal of Neurosurgery* 2013; 1-4.
- Li, J., Zhang, H., Wang, L., Yang, C., Lai, H., Zhang, W., Chen, X., Wang, J., 2015. Comparative study of IDH1 mutations in glioma by High Resolution

- Melting Analysis, immunohistochemistry and direct DNA sequencing. *Molecular Medicine Report* 12;4376-4381.
- Louis, D.N., Perry, A., Reifenberger, G., von Deimling, A., Figarella-Branger, D., Cavenee, W.K., Ohgaki, H., Wiestler, O.D., Kleihues, P., Ellison, D.W., 2016. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. *Acta Neuropathologica* 131, 803–820. doi:10.1007/s00401-016-1545-1.
- Louis, D.N., Ohgaki, H., Wiestler, O.D., Cavenee, W.K., 2007. WHO Classification of Tumors of the central nervous system 4, 8-80.
- Molenaar, R.J., Verbaan, D., Lamba, S., Zanon, C., Jeuken, J.W.M., Boots-Sprenger, S.H.E., Wesseling, P., Hulsebos, T.J.M., Troost, D., van Tilborg, A.A., Leenstra, S., Vandertop, W.P., Bardelli, A., van Noorden, C.J.F., Bleeker, F.E., 2014. The combination of IDH1 mutations and MGMT methylation status predicts survival in glioblastoma better than either IDH1 or MGMT alone. *Neuro-Oncology* 16, 1263–1273. doi:10.1093/neuonc/nou005.
- Mondesir, J., Willekens, C., Touat, M., Botton, S.D., 2016. IDH1 and IDH2 mutations as novel therapeutic targets: current perspectives. *Journal of Blood Medicine* 7, 171-180.
- Nuovo, G., 2016. False-Positive Results in Diagnostic Immunohistochemistry are Related to Horseradish Peroxidase Conjugates in Commercially Available Assays. *Annals of Diagnostic Pathology*, 25; 54-59.
- Ostrom, Q.T., Gittleman, H., Truitt, G., Boscia, A., Kruchko, C., Sloan, J.S.B., 2018. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2011-2015. *Neuro-Oncology* 20 (S4), 1-86.
- Park, S.-H., 2012. IDH1 mutation of gliomas with long-term survival analysis. *Oncology Reports*. doi:10.3892/or.2012.1994.
- Pascal, L.e., True, L.D., Campbell, D.D., Deutsch, E.W., Risk, M., Coleman, I.M., Eichner, L.J., Nelson, P.S., Liu, A.Y., 2008. Correlation of mRNA and Protein Levels: Cell Type-Specific Gene Expression of Cluster Designation Antigens in the Prostate. *BMC Genomics*, 9;246. doi: 10.1186/1471-2164-9-246.
- Piragua, S.C., Jansen, M., Ganguly, A., Kim, J.C., David, Louis, D.N., Nutt, C.L., 2010. Mutant IDH1-Specific Immunohistochemistry Distinguishes Diffuse Astrocytoma from Astrocytosis. *Acta Neuropathol*, 119(4): 509-511.
- Pyo, J., Kim, N.Y., Kim, R.H.J., Kang, G., 2016. Concordance analysis and diagnostic test accuracy review of IDH1 immunohistochemistry in glioblastoma. *Brain Tumor Pathol* 2016.
- Ramosvara, J.A., 2010. Principles and methods of immunohistochemistry. Jean-Charles Gautier, Drug safety evaluation: Methods and protocols, methods and molecular biology, vol 691.
- Rasmussen, B.K., Hansen, S., Laursen, R.J., Kostejanetz, M., Schultz, H., Norgard, B.M., Guldberg, R., Gradel, K.O., 2017. Epidemiology of Glioma: Clinical Characteristics, Symptoms, and Predictors of Glioma

- Patients Grade I-IV in the Danish Neuro-Oncology Registry. *J Neurooncol.* doi: 10.1007/s11060-017-2607-5.
- Reuss, D.E., Sahm, F., Schrimpf, D., Wiestler, B., Capper, D., Koelsche, C., Schweizer, L., Korshunov, A., Jones, D.T.W., Hovestadt, V., Mittelbronn, M., Schittenhelm, J., Herold-Mende, C., Unterberg, A., Platten, M., Weller, M., Wick, W., Pfister, S.M., von Deimling, A., 2015. ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an “integrated” diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma. *Acta Neuropathologica* 129, 133–146. doi:10.1007/s00401-014-1370-3.
- Shaban, Z.M., Al-Aubaidy, S.R., Hameedi, A.D., 2018. IDH1 mutation in glioma in Baghdad by immunohistochemical study. *International Journal of Genetics and Genomics* 6(1); 1-7.
- Singh, A., Sipayya, V., Sharma, I., Sharma, K., 2012. Immunohistochemical expression of IDH1 in gliomas: A tissue microarray-based approach. *Journal of Cancer Research and Therapeutics* 8, 598. doi:10.4103/0973-1482.106567.
- Stupp, R., Brada, M., Van Den Bent, M.J., Tonn, J.C., Pentheroudakis, G., 2014. High grade glioma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. *Annals of Oncology* 25; iii95-iii101.
- Takano, S., Ishikawa, E., Sakamoto, N., Matsuda, M., Akutsu, H., Noguchi, M., Kato, Y., Yamamoto, T., Matsumura, A., 2016. Immunohistochemistry on IDH 1/2, ATRX, p53 and Ki-67 substitute molecular genetic testing and predict patient prognosis in grade III adult diffuse gliomas. *Brain Tumor Pathology* 33, 107–116. doi:10.1007/s10014-016-0260-x.
- True, L.D., 2008. Quality Control in Molecular Immunohistochemistry. *Histochem Cell Biol*, 130 (3); 473-480.
- Zou, P., Xu, H., Chen, P., Yan, Q., Zhao, L., Zhao, P., Gu, A., 2013. IDH1/IDH2 Mutations Define the Prognosis and Molecular Profiles of Patients with Gliomas: A Meta-Analysis. *PLoS ONE* 8, e68782. doi:10.1371/journal.pone.0068782.